Century Therapeutics Appoints New Directors to Accelerate iPSC Therapy Development
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 09 2025
0mins
Source: Newsfilter
- New Board Members: Century Therapeutics has appointed Dr. Han Lee and Dr. Martin Murphy to its Board of Directors, with Dr. Lee joining the Audit and Compensation Committees and Dr. Murphy joining the Compensation and Nominating Committees, aiming to leverage their expertise to advance the company's iPSC-derived therapies towards clinical trials.
- Rich Leadership Experience: Dr. Han Lee, previously President and CFO of ImmPACT Bio, brings extensive capital formation and corporate development experience, which is expected to significantly enhance Century's financial strategy and growth direction.
- Industry Influence: Dr. Martin Murphy has a broad background in life science investment and company creation, having held key positions in several renowned firms, and his addition will strengthen Century's strategic oversight capabilities in the biotechnology sector.
- Accelerating Clinical Progress: CEO Brent Pfeiffenberger stated that the new board members will help expedite the clinical development of iPSC-derived therapies like CNTY-813, aiming to provide potentially curative treatment options for patients with high-impact diseases.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IPSC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IPSC
Wall Street analysts forecast IPSC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IPSC is 4.30 USD with a low forecast of 2.00 USD and a high forecast of 6.60 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 2.010
Low
2.00
Averages
4.30
High
6.60
Current: 2.010
Low
2.00
Averages
4.30
High
6.60
About IPSC
Century Therapeutics, Inc. is a biotechnology company. The Company is focused on developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies and autoimmune diseases. The Company has created allogeneic cell therapy platform that includes induced pluripotent stem cells (iPSCs), differentiation know-how to generate immune effector cells from iPSCs, or iPSC- derived cells, clustered regularly interspaced short palindromic repeats, to incorporate multiple transgenes and remove target genes. The Company’s product candidates include CNTY-101, CNTY-308, CNTY-341, CNTY-107, and CNTY-104. Its lead product candidate CNTY-101 is a CAR-iNK cell therapy with six precision gene edits in a Phase I clinical trial for patients with B-cell mediated autoimmune diseases. CNTY-308 is a CD19-targeted, iPSC derived CAR T cell therapy. CNTY-341 is a dual-targeted CD19 and CD22 iPSC-derived CAR-T cell therapy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Why Century Therapeutics (IPSC) Is an Excellent Option for Value Investors
Momentum Investing Overview: Momentum investing contrasts with traditional strategies by focusing on "buying high and selling higher," which can be risky if stocks lose momentum due to overvaluation.
Century Therapeutics, Inc. (IPSC): IPSC is highlighted as a strong candidate for momentum investing, showing a 3.9% price increase in four weeks and a 14.6% gain over 12 weeks, with a favorable Momentum Score of B.
Valuation and Earnings Estimates: IPSC is trading at a low Price-to-Sales ratio of 0.43, indicating it is attractively priced despite its momentum, and has a Zacks Rank #2 (Buy) due to positive earnings estimate revisions.
Quantum Computing Potential: The article also discusses the rapid advancement of quantum computing, with major tech companies integrating it into their infrastructure, and highlights investment opportunities in this emerging field.
Continue Reading
Century Therapeutics Appoints New Directors to Accelerate iPSC Therapy Development
- New Board Members: Century Therapeutics has appointed Dr. Han Lee and Dr. Martin Murphy to its Board of Directors, with Dr. Lee joining the Audit and Compensation Committees and Dr. Murphy joining the Compensation and Nominating Committees, aiming to leverage their expertise to advance the company's iPSC-derived therapies towards clinical trials.
- Rich Leadership Experience: Dr. Han Lee, previously President and CFO of ImmPACT Bio, brings extensive capital formation and corporate development experience, which is expected to significantly enhance Century's financial strategy and growth direction.
- Industry Influence: Dr. Martin Murphy has a broad background in life science investment and company creation, having held key positions in several renowned firms, and his addition will strengthen Century's strategic oversight capabilities in the biotechnology sector.
- Accelerating Clinical Progress: CEO Brent Pfeiffenberger stated that the new board members will help expedite the clinical development of iPSC-derived therapies like CNTY-813, aiming to provide potentially curative treatment options for patients with high-impact diseases.
Continue Reading